Pneumococcal vaccine development

References

• Austrian R. Pneumococci. In: Microbiology Third Edition. Davis BD, Dulbecco R, Eisen HN, Ginsberg HS (Eds). Harper and Row, NY, USA, 595–606 (1980).
   Google Scholar
• Brown JS, Hussel T, Gilliland SM et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. PNAS99, 16969–16974 (2002).
   PubMed Web of Science ®Google Scholar
• Butcher S, Chachel H, Lord JM. Ageing and the neutrophil: no appetite for killing? Immunology 100, 411–416 (2000).
   Google Scholar
• Musher DM, Phan HM, Watson DA, Baughn DA. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia. J. Infect. Dis. 182,158–167 (2000).
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Musher DM, Cetron MS et al Reduction in functional activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29,281–288 (1999).
   PubMed Web of Science ®Google Scholar
• Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol Rev 16,308–318 (2003).
   Google Scholar
• Törling J, Hedlund J, Bossen-Konradsen H, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 22, 96–103 (2003).
   Google Scholar
• Kruetzmann S, Rosado MM, Weber H et al. Human immunoglobulin M memory B-cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp. Med. 197,939–945 (2003).
   PubMed Web of Science ®Google Scholar
• Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 cell responses in vivo. J. Immun. 172, 5194–5199 (2004).
   Google Scholar
• Knapp S, Hareng L, Rijneveld AW et al. Activation of neutrophils and inhibition of the pro-inflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia. JID 189, 1506–1514 (2004).
   PubMed Web of Science ®Google Scholar
• Kadioglu A, Coward W, Colston MJ, Hewitt CRA, Andrew PW. CD4 T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect. Immun. 72, 2689–2697 (2004).
   Google Scholar
• Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 22,927–946 (2003).
   Web of Science ®Google Scholar
• •Reviews the clinical trials and clinical impact of the pneumococcal polysaccharide vaccine (PPV) in adults.
   Google Scholar
• Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. The Cochrane Library 1. John Wiley & Sons, Chichester, UK (2004).
   Google Scholar
• Hsu KK, Pelton SI. Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines 2, 619–631 (2003).
   PubMedGoogle Scholar
• Klugman KP, Madhi SA, Huebner RE et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl. J. Med. 349,1341-1348 (2003).
   Google Scholar
• Black S, Shinefield H, Fireman B et al Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. 19,187–195 (2000).
   Google Scholar
• •Describes the impact of pneumococcal conjugate vaccine (PCV) on pediatric invasive pneumococcal diseases.
   Google Scholar
• O'Brien KL, Moulton LH, Reid R et al. Efficacy and safety of 7-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 362,355–361 (2003).
   Google Scholar
• Whitney CG, Farley M, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl. J. Med. 348,1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• •Describes the PCV postlicensure impact, including the nonimmunized age group.
   Google Scholar
• Black SB, Shinefield H, Baxter R et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J. 23, 485–489 (2004).
   PubMed Web of Science ®Google Scholar
• •Describes the antibody correlates of protection in relation to pediatric PCV.
   Google Scholar
• Jóclar L, Butler J, Carlone G et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccines formulations for use in infants. Vaccine 21,3265–3272 (2003).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl. J. Med. 348,1747–1755 (2003).
   PubMed Web of Science ®Google Scholar
• •Describes the limitations of PPV with regards to adult pneumococcal pneumonia.
   Google Scholar
• Honkanen PO, Keistinen T, Miettinen L et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 17,2493–2500 (1999).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med. 159,2437–2442 (1999).
   PubMed Web of Science ®Google Scholar
• Wagner C, Popp W Pasch Vlasich, M. C, Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology49,246–250 (2003).
   PubMed Web of Science ®Google Scholar
• Zysk G, Bethe G, Nau R et al Immune response to capsular polysaccharide and surface proteins of Streptococcus pneumoniae in patients with invasive pneumococcal disease. J. Infect. Dis. 187,330–333 (2003).
   PubMed Web of Science ®Google Scholar
• Scott A, Obiero J, Marsh K. Susceptibility to pneumococcal pneumonia is determined by unresponsiveness to pneumococcal polysaccharides in general rather than by serotype-specific immunodeficiency. ISPPD Abstract (2002).
   Google Scholar
• Hedlund J, Ortqvist A, Konradsen HB, Kahn M. Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scand. j Infect. Dis. 32, 281–286 (2000).
   PubMed Web of Science ®Google Scholar
• Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect. Immun. 67,5979-5984 (1999).
   Google Scholar
• Yee AMF, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between Fc7RIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30,25-28 (2000).
   Google Scholar
• Smithson SL, Srivastava N, Westerink MAJ. Differential Vgene expression detected in the immune response to Streptococcus pneumoniae capsular polysaccharide between elderly and young adults. Hybridoma and Hybridomics 21, 19–24 (2002).
   Google Scholar
• Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 22,1362–1371 (2004).
   PubMed Web of Science ®Google Scholar
• •Reviews adult immunogenicity studies with PCV.
   Google Scholar
• Musher DM, Groover JE, Watson DA, Rodriguez-Barradas MC, Baugh RE. IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides. Clin. Infect. Dis. 27, 1487–1490 (1998).
   Google Scholar
• Zielen S, Btirhing I, Strnad N, Reichenbach J, Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect. Immun. 68,1435-1440 (2000).
   Google Scholar
• Soininen A, Seppälä I, Nieminen T, Eskola J, Käythy H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17,1889–1897 (1999).
   PubMed Web of Science ®Google Scholar
• Vernacchio L, Romero-Steiner S, Martinez JE et al Comparison of opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle-cell disease. J. Infect. Dis. 181,1162–166 (2000).
   PubMed Web of Science ®Google Scholar
• Shelly MA, Schiff G, Wernette C et al. Evaluation of a 9-valent CRM197 conjugated pneumococcal polysaccharide vaccine in elderly adults. ICAAC Poster G-902a (2003).
   Google Scholar
• Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2/, 303–311 (2002).
   Google Scholar
• Jackson LA, Benson P, Sneller VP et al Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281, 243–248 (1999).
   PubMed Web of Science ®Google Scholar
• Concepcion N, Frasch C. Pneumococcal Type 22F polysaccharide adsorption improves the specificity of a pneumococcal polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol 8,266–272 (2001).
   Google Scholar
• •Describes the benefits of using antipneumococcal polysaccharide enzyme- linked immunosorbent assay (ELISA) including 22F inhibition.
   Google Scholar
• Lazou-Ahren I, Janson H, Forsgren A, Riesbeck K. Protein D expression promotes the adherence and internalization of nontypeable Haemophilus intluenzae into human monocytic cells. Microb. Pathog. 31, 151–158 (2001).
   Google Scholar
• Bogaert D, De Groot R, Hermans PWM. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect. Dis. 4,144–154 (2004).
   PubMed Web of Science ®Google Scholar
• Swiatlo E, Champlin FR, Holman SC, Wilson WW, Watt JM. Contribution of choline-binding proteins to cell surface properties of Streptococcus pneumoniae. Infect. Immun. 70,412–415 (2002).
   Google Scholar
• Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 70,2526–2534 (2002).
   PubMed Web of Science ®Google Scholar
• Weiser JN, Bae D, Fasching C et al Antibody-enhanced pneumococcal adherence requires IgAl protaese. Proc. Natl Acad. Scill USA 100,4215–4220 (2003).
   PubMed Web of Science ®Google Scholar
• Tong HH, Blue LE, James MA, De Maria TF. Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharageal colonization and development of otitis media in the chinchilla model. Infect. Immun. 68,921–924 (2000).
   Google Scholar
• Kadioglu A, Taylor S, Iannelli F et al. Upper and lower respiratory tract in infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Infect. Immun. 70,2886–2890 (2002).
   PubMed Web of Science ®Google Scholar
• Weiser JN, Lapoor M. Effect of intrastrain variation in the amount of capsular polysaccharide on genetic transformation of Streptococcus pneumoniae implications for virulence studies of encapsulated strains. Infect. Immun. 67,3690–3692 (1999).
   PubMed Web of Science ®Google Scholar
• Ghaffar F, Friedland IR, McCracken CH Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr. Infect. Dis. J. 18,638–646 (1999).
   Google Scholar
• Greenwood B. The epidemiology of pneumococcal infection in children in the developing world. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 354,777-785 (1999).
   Google Scholar
• Simell B, Korkeila M, Pursiaenen H, Kilpi TM, Käihty H. Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin A, pneumolysin and pneumococcal surface protein A in children. J Infect. Dis. 183, 887–896 (2001).
   Google Scholar
• Kilpi T, Terhi MD, Herva E et al Bacteriology of acute otitis media in a cohort of Finnish children followed for the first 2 years of life. Pediatr. Infect. Dis. J. 20, 654–662 (2001).
   Google Scholar
• Mc Cool TL, Cate TR, Moy G, Weiser JN. The immune response to pneumococcal proteins during experimental human carriage. J. Exp. Med. 195,359–365 (2003).
   Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in daycare centers. Pediatr. Infect. Dis. J. 22,532–540 (2003).
   PubMed Web of Science ®Google Scholar
• Klugman KR Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect. Dis. 1,85–91(2001).
   Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococal conjugate vaccine against acute otitis media. N Engl. J. Med. 344, 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• •Describes the impact of PCV on pediatric otitis including serotype replacement.
   Google Scholar
• Kilpi T, Ahman H, Jokinen J et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37,1155-1164 (2003).
   Google Scholar
• Veenhoven R, Bogaert D, Uiterwaal C et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomized trial. Lancet 361,2189–2195 (2003).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Mason EO, Wald ER et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113,443–449 (2004).
   PubMed Web of Science ®Google Scholar
• Straetemans M, Sanders EM, Veenhoven RH et al. Review of randomized controlled trials on pneumococcal vaccination for prevention of otitis media. Pediatr. Infect. Dis. J. 22,515–524 (2003).
   Google Scholar
• Feikin DR, Klugman KR Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35,547–555 (2002).
   PubMed Web of Science ®Google Scholar
• Sandgren A, Sjöströrn K, Olsson-Liljequist B et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J Infect. Dis. 189,785–796 (2004).
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Griffiths DT, Meats E et al Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype-and clone-specific differences in invasive disease potential. J. Infect. Dis. 187, 1424–1432 (2003).
   PubMed Web of Science ®Google Scholar
• Hanaga WP, Auranen K, Syrjänen R et al. Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect. Immun. 72,76–81 (2004).
   PubMed Web of Science ®Google Scholar
• Wizeman TM, Heinrichs JH, Adamou et al. Use of a whole genome approach to identify molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69,1593–1598 (2001).
   PubMed Web of Science ®Google Scholar
• Ren B, Szalai AJ, Hollingshead SK, Briles DE. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72,114–122 (2004).
   PubMed Web of Science ®Google Scholar
• Ken B, Szalai AJ, Thomas O, Hollingshead SK, Bales DE. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect. Immun. 71,75-85 (2003).
   Google Scholar
• Briles DE, Hollingshead SK, Paton JC et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect. Dis. 188,339–348 (2003).
   PubMed Web of Science ®Google Scholar
• Kagioglu A, Andrew PW, The innate immune response to pneumococcal lung infection: the untold story. Trends IrmnunoL 25,143–149 (2004).
   PubMed Web of Science ®Google Scholar
• Alcantara RB, Preheim LC, Gentry-Nielsen MJ. Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia. Infect. Immun. 69,3569-3575 poly.
   Google Scholar
• Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J. Infect. Dis. 183,827–830 (2001).
   PubMed Web of Science ®Google Scholar
• Huo Z, Spencer O, Miles J et al. Antibody responses to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients. Vaccine 22, 1157–1161 (2004).
   PubMed Web of Science ®Google Scholar
• Adamou JE, Heinrichs JH, Erwin AL et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect. Immun. 69,949–958 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Masi AW, Barniak V et al. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae protects mice against intranasal pneumococcal challenge. Infect. Immun. 69,3827–3836 (2001).
   PubMed Web of Science ®Google Scholar
• Hamel J, Charland N, Pineau I et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect. Immun. 72, 2659–2670 (2004).
   PubMed Web of Science ®Google Scholar
• Jarva H, janulczyk Hellwage, R. Zipfel, J. PF, Björck L, Meri S. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds short consensus repeats 8–11 of factor H. J. ImmunoL 168,1886–1894 (2001).
   Google Scholar
• Duthy TG, Ormsby RJ, Giannakis E et al. The human complement regulator factor H binds pneumococcal surface protein PspC via short coknsensus repeats 13 to 15. Infect. Immun. 70,5604-5611 (2002).
   Google Scholar
• lanelli Oggioni, F. MR, Pozzi G. Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene 28, 63–71 (2002).
   Google Scholar
• Murdoch C, Read RC, Zhang Q, Finn A. Choline-binding protein A of Streptococcus pneumoniae elicits chemokine production and expression of intercellular adhesion molecule 1 (CD54) by human alveolar epithelial cells. J Infect. Dis. 186, 1253–1260 (2002).
   Google Scholar
• Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect. Immun. 69, 5997–6003 (2001).
   PubMed Web of Science ®Google Scholar
• Balanchandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollilngshead SK, Briles DE. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 70,2526–2534 (2002).
   PubMed Web of Science ®Google Scholar
• Briles DE, Paton JC, Sampson JS et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PspA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 68,796–800 (2000).
   PubMed Web of Science ®Google Scholar
• Malley R, Lipsitch M Stack A et al. Intranansal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumocicci. Infect. Immun. 69, 4870–4873 (2001).
   Google Scholar
• Long JP, Tong HH, DeMaria TF. Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis model. Infect. Immun. 72,4309–4313 (2004).
   Google Scholar
• Mi QS. Highly reduced protection against Streptococcus pneumoniae after deletion of a single heavy chain gene in mouse. Proc. Natl Acad. Sci. USA 97,6031–6036 (2000).
   PubMed Web of Science ®Google Scholar
• Hausdorff WE Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur. j Pediatr. 161, S135—S139 (2002).
   Web of Science ®Google Scholar
• Schuchat A (Centers of Disease Control and Prevention). Presentation at the 4th International Symposium on Pneumococci and Pneumococcal Diseases, Helsinki, Finland, 9–13 May (2004).
   Google Scholar